Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Camostat mesylate (HB3595)
Description:Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Purity:>98%
Chaetoglobosin A (HB3828)
Description:Antibiotic with antibacterial, antifungal and cytotoxic activity. Selectively induces apoptosis of CLL cells.
Purity:>98%
Chalcomycin (HB3830)
Description:Macrolide antibiotic with antimicrobial and antibacterial activity
Purity:>96%
Clindamycin hydrochloride (HB4364)
Description:Antibiotic. Protein synthesis inhibitor
Purity:>98%
Cycloheximide (HB2904)
Description:Eukaryotic protein synthesis inhibitor. Apoptosis inducer.
Purity:>95%